Accurate, sensitive mass techniques required to identify specific peak of certain nitrosamines
Continuing its investigation into the presence of potential carcinogenic materials in various medicines, on May 28, the US FDA…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
sartans
Carcinogens under the scan
As trace amounts of cancer causing contaminants continue to crop up in certain medicines, pharma companies are upgrading their…
After sartans and ranitidine, where will NDMA show up next?
While regulators and pharma companies try to understand if it is the product or the process that is at fault in the ranitidine…